SI-BONE, Inc. (SIBN) witnessed a remarkable 9.39% surge in its stock price on Tuesday, driven by robust fourth-quarter financial results and a strong outlook for 2025. The medical device company specializing in musculoskeletal disorders of the sacropelvic anatomy reported record fourth-quarter worldwide revenue of $49 million, up 26% year-over-year, driven by strong demand for its innovative product portfolio.
The company achieved a significant milestone by delivering positive adjusted EBITDA of $1.9 million in the fourth quarter, marking its first-ever quarterly profit. For the full year 2024, SI-BONE's adjusted EBITDA loss narrowed by over 70% to $5.1 million, highlighting the scalability of its business model and progress towards generating positive free cash flow.
With new product launches like Granite 9.5 and TNT exceeding adoption expectations and continued momentum in its core SI joint fusion business, SI-BONE is well-positioned for sustained growth. The company guided for 2025 worldwide revenue of $193.5 million to $195.5 million, representing year-over-year growth of approximately 16% to 17%, and expects to achieve positive adjusted EBITDA for the full year.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。